BR112013000923A2 - método de tratamento de hiv ou aids - Google Patents

método de tratamento de hiv ou aids

Info

Publication number
BR112013000923A2
BR112013000923A2 BR112013000923A BR112013000923A BR112013000923A2 BR 112013000923 A2 BR112013000923 A2 BR 112013000923A2 BR 112013000923 A BR112013000923 A BR 112013000923A BR 112013000923 A BR112013000923 A BR 112013000923A BR 112013000923 A2 BR112013000923 A2 BR 112013000923A2
Authority
BR
Brazil
Prior art keywords
hiv
treatment method
aids treatment
aids
polypeptide
Prior art date
Application number
BR112013000923A
Other languages
English (en)
Inventor
Vasilis Paspaliaris
Original Assignee
Adistem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010903143A external-priority patent/AU2010903143A0/en
Application filed by Adistem Ltd filed Critical Adistem Ltd
Publication of BR112013000923A2 publication Critical patent/BR112013000923A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

método de tratamento de hiv ou aids. a presente invenção refere-se a um método de tratar o hiv ou a aids que compreende administrar uma composição compreendendo um polipeptídeo que compreende lkktetq (seq id no: 1) ou uma variante dela, ou administrar uma composição compreendendo um peptidomimético de um polipeptídeo compreendendo a sequência de aminoácidos lkktetq (seq id no: 1) ou uma variante dela.
BR112013000923A 2010-07-14 2011-07-14 método de tratamento de hiv ou aids BR112013000923A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010903143A AU2010903143A0 (en) 2010-07-14 Method of treatment of HIV or Aids
PCT/AU2011/000878 WO2012006667A1 (en) 2010-07-14 2011-07-14 Method of treatment of hiv or aids

Publications (1)

Publication Number Publication Date
BR112013000923A2 true BR112013000923A2 (pt) 2016-05-17

Family

ID=45468803

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000923A BR112013000923A2 (pt) 2010-07-14 2011-07-14 método de tratamento de hiv ou aids

Country Status (7)

Country Link
US (1) US20130143795A1 (pt)
EP (1) EP2593120B1 (pt)
JP (1) JP2013531683A (pt)
AU (1) AU2011279539A1 (pt)
BR (1) BR112013000923A2 (pt)
ES (1) ES2627936T3 (pt)
WO (1) WO2012006667A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101019A (ja) * 1988-10-05 1990-04-12 Genichiro Soma 抗エイズ剤
US9056087B2 (en) * 2001-08-29 2015-06-16 Regenerx Biopharmaceuticals, Inc. Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
US20050020495A1 (en) * 2001-10-24 2005-01-27 Martins Eduardo Bruno Guimaraes Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
EP1497322A4 (en) * 2002-02-06 2006-11-08 Regenerx Biopharmaceuticals TREATMENT OF INFECTIONS AND OTHER DISORDERS
MXPA05010390A (es) * 2003-03-31 2005-11-04 Regenerx Biopharmaceuticals Composiciones y metodos para la liberacion de timosina beta 4, analogos, isoformas y otros derivados.
WO2006076255A2 (en) * 2005-01-11 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing microbial eye infection
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
WO2009033816A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
WO2009151689A2 (en) * 2008-03-17 2009-12-17 Regenerx Biopharmaceuticals, Inc. Improved beta thymosin fragments

Also Published As

Publication number Publication date
EP2593120A4 (en) 2014-01-01
ES2627936T3 (es) 2017-08-01
US20130143795A1 (en) 2013-06-06
EP2593120B1 (en) 2017-03-08
AU2011279539A1 (en) 2013-03-07
JP2013531683A (ja) 2013-08-08
EP2593120A1 (en) 2013-05-22
WO2012006667A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX351682B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
GT201300295A (es) "composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales"
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
RS53236B (en) BETA-AMYLOIDOSIS PEPTIDES
BRPI0906710B8 (pt) peptídeo derivado de pres modificado hidrofóbico de vírus da hepatite b (hbv) , peptídeo e composição farmacêutica
BR112014007675A2 (pt) tratamento de doença articular degenerativa
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
MX2010007670A (es) Uso de sal de acido acetilsalicilico para tratamiento de infecciones virales.
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
NZ601142A (en) Composition for improving brain function and method for improving brain function
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
WO2010000851A3 (en) Methods for modulating angiogenesis via dystrophin dp71
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
PE20121553A1 (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2373 DE 28-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.